Spesolimab is a humanized monoclonal antibody that blocks the activation of the IL-36 receptor (IL-36R) [172], and is presently being investigated in phase II trials for moderate to severe palmoplantar pustulosis [183]. The gene discussed is IL1RL2; the disease is palmoplantar pustulosis.